+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liposomal Doxorubicin Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • August 2024
  • Region: Global
  • The Business Research Company
  • ID: 5991010
Liposomal doxorubicin is a form of the chemotherapy drug doxorubicin enclosed within lipid bilayers, forming tiny vesicles known as liposomes. This encapsulation modifies how the drug moves through the body, leading to longer circulation in the bloodstream and increased accumulation at tumor sites due to improved permeability and retention effects. Liposomal doxorubicin is employed in treating different cancers such as ovarian cancer, breast cancer, and Kaposi's sarcoma, potentially reducing the risk of heart-related side effects compared to traditional doxorubicin formulations.

The primary types of liposomal doxorubicin include Doxil or Caelyx, Lipodox, Myocet, and others. Doxil, also marketed as Caelyx, is a specific brand of liposomal doxorubicin used in chemotherapy for various cancer types. It is administered via injection and is applied in treating leukemia, bone sarcoma, breast cancer, endometrial cancer, kidney cancer, multiple myeloma, Kaposi sarcoma, among others. It is utilized by various end-users including hospitals, home care settings, and others.

The liposomal doxorubicin market research report is one of a series of new reports that provides liposomal doxorubicin market statistics, including liposomal doxorubicin industry global market size, regional shares, competitors with a liposomal doxorubicin market share, detailed liposomal doxorubicin market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal doxorubicin industry. This liposomal doxorubicin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liposomal doxorubicin market size has grown strongly in recent years. It will grow from $1.15 billion in 2023 to $1.23 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historical period can be ascribed to advancements in liposome formulations, favorable reimbursement policies for cancer treatments, heightened awareness regarding cancer screening programs, improved healthcare infrastructure, and a rising preference among patients for minimally invasive cancer therapies.

The liposomal doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.61 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth is anticipated due to increasing awareness about cancer treatment options, escalating clinical trials, greater adoption of combination therapies, higher healthcare spending, and growing favor towards targeted treatments. Key trends anticipated in this period encompass the integration of artificial intelligence and machine learning algorithms in drug discovery, the application of 3D printing technologies, magnetic targeting techniques, innovative approaches such as tumor-penetrating peptides and ultrasound-mediated drug delivery, and advancements in drug delivery mechanisms.

The increasing prevalence of cancer is expected to drive the growth of the liposomal doxorubicin market in the future. Cancer encompasses a range of diseases originating from abnormal cell proliferation that breaches normal tissue boundaries, potentially spreading to other organs or neighboring areas. Factors contributing to rising cancer rates include an aging population, lifestyle changes, environmental exposures, and advancements in diagnostic techniques. Liposomal doxorubicin plays a crucial role in cancer treatment by enhancing drug delivery to tumors, minimizing toxicity, and improving treatment outcomes. For example, the American Cancer Society Inc. anticipates 1.9 million new cancer cases in the US in 2023, up from over 1.8 million in 2020, underscoring the market's growth driven by cancer's increasing prevalence.

Key players in the liposomal doxorubicin market are concentrating on advancing drug delivery systems such as PEGylated liposomes to enhance the pharmacokinetics and distribution of doxorubicin, thereby improving patient outcomes. These innovations ensure drugs are targeted more effectively to cancer cells while reducing side effects. For instance, in May 2022, Accord Healthcare Limited introduced Zolsketil, a pegylated liposomal 2mg/ml concentrate for infusion dispersion, as a generic alternative to doxorubicin, a widely used cancer treatment.

In October 2021, Padagis US LLC collaborated with Ayana Pharma Ltd. to introduce an AB-rated generic version of Doxil (Doxorubicin Liposome Injection), addressing the drug's current shortage listed by the FDA. Doxil is utilized in treating various cancers including ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. Ayana Pharma Ltd. is based in Israel and specializes in pharmaceuticals.

Major companies operating in the liposomal doxorubicin market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd, Baxter International Inc., Astellas Pharma, Sun Pharmaceutical Industries Ltd, Jazz Pharmaceuticals, Cipla Inc., Endo Pharmaceuticals, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila, Accord Healthcare Limited, Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd, TTY Biopharm Company Limited, SRS Life Sciences.

North America was the largest region in the liposomal doxorubicin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liposomal doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liposomal doxorubicin market consists of sales of Doxil and Lipodox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Liposomal Doxorubicin Market Characteristics3. Liposomal Doxorubicin Market Trends And Strategies
4. Liposomal Doxorubicin Market - Macro Economic Scenario
4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market
5. Global Liposomal Doxorubicin Market Size and Growth
5.1. Global Liposomal Doxorubicin Market Drivers and Restraints
5.1.1. Drivers Of The Market
5.1.2. Restraints Of The Market
5.2. Global Liposomal Doxorubicin Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Liposomal Doxorubicin Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Liposomal Doxorubicin Market Segmentation
6.1. Global Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Doxil Or Caelyx
  • Lipodox
  • Myocet
  • Other Products
6.2. Global Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Parenteral
  • Other Routes Of Administration
6.3. Global Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Leukemia
  • Bone Sarcoma
  • Breast Cancer
  • Endometrial Cancer
  • Kidney Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Other Applications
6.4. Global Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Centers
  • Other End-Users
7. Liposomal Doxorubicin Market Regional And Country Analysis
7.1. Global Liposomal Doxorubicin Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Liposomal Doxorubicin Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Liposomal Doxorubicin Market
8.1. Asia-Pacific Liposomal Doxorubicin Market Overview
(Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies)
8.2. Asia-Pacific Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Liposomal Doxorubicin Market
9.1. China Liposomal Doxorubicin Market Overview
9.2. China Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Liposomal Doxorubicin Market
10.1. India Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Liposomal Doxorubicin Market
11.1. Japan Liposomal Doxorubicin Market Overview
11.2. Japan Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Liposomal Doxorubicin Market
12.1. Australia Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Liposomal Doxorubicin Market
13.1. Indonesia Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Liposomal Doxorubicin Market
14.1. South Korea Liposomal Doxorubicin Market Overview
14.2. South Korea Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Liposomal Doxorubicin Market
15.1. Western Europe Liposomal Doxorubicin Market Overview
15.2. Western Europe Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Liposomal Doxorubicin Market
16.1. UK Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Liposomal Doxorubicin Market
17.1. Germany Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Liposomal Doxorubicin Market
18.1. France Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Liposomal Doxorubicin Market
19.1. Italy Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Liposomal Doxorubicin Market
20.1. Spain Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Liposomal Doxorubicin Market
21.1. Eastern Europe Liposomal Doxorubicin Market Overview
21.2. Eastern Europe Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Liposomal Doxorubicin Market
22.1. Russia Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Liposomal Doxorubicin Market
23.1. North America Liposomal Doxorubicin Market Overview
23.2. North America Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Liposomal Doxorubicin Market
24.1. USA Liposomal Doxorubicin Market Overview
24.2. USA Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Liposomal Doxorubicin Market
25.1. Canada Liposomal Doxorubicin Market Overview
25.2. Canada Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Liposomal Doxorubicin Market
26.1. South America Liposomal Doxorubicin Market Overview
26.2. South America Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Liposomal Doxorubicin Market
27.1. Brazil Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Liposomal Doxorubicin Market
28.1. Middle East Liposomal Doxorubicin Market Overview
28.2. Middle East Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Liposomal Doxorubicin Market
29.1. Africa Liposomal Doxorubicin Market Overview
29.2. Africa Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Liposomal Doxorubicin Market Competitive Landscape And Company Profiles
30.1. Liposomal Doxorubicin Market Competitive Landscape
30.2. Liposomal Doxorubicin Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Johnson & Johnson
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. AbbVie Inc.
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. AstraZeneca plc
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Takeda Pharmaceutical Company
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Liposomal Doxorubicin Market Other Major And Innovative Companies
31.1. Eli Lilly and Company
31.2. Amgen Inc.
31.3. Teva Pharmaceutical Industries Ltd
31.4. Baxter International Inc.
31.5. Astellas Pharma
31.6. Sun Pharmaceutical Industries Ltd
31.7. Jazz Pharmaceuticals
31.8. Cipla Inc.
31.9. Endo Pharmaceuticals
31.10. Lupin Limited
31.11. Mallinckrodt Pharmaceuticals
31.12. Zydus Cadila
31.13. Accord Healthcare Limited
31.14. Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd
31.15. TTY Biopharm Company Limited
32. Global Liposomal Doxorubicin Market Competitive Benchmarking33. Global Liposomal Doxorubicin Market Competitive Dashboard34. Key Mergers And Acquisitions In The Liposomal Doxorubicin Market
35. Liposomal Doxorubicin Market Future Outlook and Potential Analysis
35.1 Liposomal Doxorubicin Market In 2028 - Countries Offering Most New Opportunities
35.2 Liposomal Doxorubicin Market In 2028 - Segments Offering Most New Opportunities
35.3 Liposomal Doxorubicin Market In 2028 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright And Disclaimer

Executive Summary

Liposomal Doxorubicin Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liposomal doxorubicin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for liposomal doxorubicin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liposomal doxorubicin market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Product: Doxil Or Caelyx; Lipodox; Myocet; Other Products
2) By Route Of Administration: Parenteral; Other Routes Of Administration
3) By Application: Leukemia; Bone Sarcoma; Breast Cancer; Endometrial Cancer; Kidney Cancer; Multiple Myeloma; Kaposi Sarcoma; Other Applications
4) By End-Users: Hospitals; Homecare; Other End-Users

Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; AstraZeneca plc; Takeda Pharmaceutical Company

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • AstraZeneca plc
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd
  • Baxter International Inc.
  • Astellas Pharma
  • Sun Pharmaceutical Industries Ltd
  • Jazz Pharmaceuticals
  • Cipla Inc.
  • Endo Pharmaceuticals
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Zydus Cadila
  • Accord Healthcare Limited
  • Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd
  • TTY Biopharm Company Limited
  • SRS Life Sciences

Methodology

Loading
LOADING...